| Literature DB >> 26729375 |
Elizabeth V Arkema1, Andreas Jönsen2, Lars Rönnblom3, Elisabet Svenungsson4, Christopher Sjöwall5, Julia F Simard6.
Abstract
OBJECTIVE: To develop and investigate the utility of several different case definitions for systemic lupus erythematosus (SLE) using national register data in Sweden.Entities:
Keywords: EPIDEMIOLOGY; RHEUMATOLOGY; STATISTICS & RESEARCH METHODS
Mesh:
Year: 2016 PMID: 26729375 PMCID: PMC4716148 DOI: 10.1136/bmjopen-2015-007769
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart showing how the final group of SLE cases and general population non-cases were identified through exclusion criteria. ACR, American College of Rheumatology; SLE, systemic lupus erythematosus.
Clinical characteristics for SLE cases
| Characteristics | SLE cases (N=929) |
|---|---|
| Age in 2009, mean (SD) (years) | 50.8 (16.0) |
| Age at SLE diagnosis, mean (SD) (years) | 34.3 (15.0) |
| Female, N (%) | 819 (88.2) |
| ACR criteria, N (%) | |
| Malar rash | 519 (55.9) |
| Discoid rash | 217 (23.4) |
| Photosensitivity | 610 (65.7) |
| Oral ulcer | 249 (26.8) |
| Arthritis | 734 (79.0) |
| Serositis | 386 (41.6) |
| Renal disorder | 312 (33.6) |
| Neurological disorder | 83 (8.9) |
| Haematological disorder | 588 (63.3) |
| Immunological disorder | 628 (67.6) |
| ANA positive, N (%) | 912 (98.2) |
| Total ACR Criteria, mean (SD) | 5.6 (1.4) |
ACR, American College of Rheumatology; ANA, antinuclear antibodies; SLE, systemic lupus erythematosus.
Accuracy measurements of multiple algorithms to define prevalent SLE in four counties in Sweden 2010
| Overall | Women | Men | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Algorithms | Sensitivity | PPV | NPV | Sensitivity | PPV | NPV | Sensitivity | PPV | NPV |
| ≥1 hospitalisation | 0.792 | 0.979 | 0.992 | 0.789 | 0.976 | 0.992 | 0.818 | 1.000 | 0.994 |
| ≥1 hospitalisation OR outpatient visit | 0.991 | 0.970 | 1.000 | 0.994 | 0.967 | 1.000 | 0.973 | 1.000 | 0.999 |
| ≥1 outpatient visit | 0.981 | 0.972 | 0.999 | 0.984 | 0.969 | 0.999 | 0.955 | 1.000 | 0.998 |
| ≥1 visit in a specialist clinic, hospitalisation OR outpatient visit | 0.988 | 0.975 | 1.000 | 0.990 | 0.971 | 1.000 | 0.973 | 1.000 | 0.999 |
| ≥2 hospitalisations | 0.646 | 0.982 | 0.987 | 0.648 | 0.980 | 0.986 | 0.627 | 1.000 | 0.988 |
| ≥2 hospitalisations OR outpatient visits | 0.981 | 0.975 | 0.999 | 0.983 | 0.972 | 0.999 | 0.964 | 1.000 | 0.999 |
| ≥2 outpatient visits | 0.970 | 0.977 | 0.999 | 0.974 | 0.974 | 0.999 | 0.936 | 1.000 | 0.998 |
| ≥2 hospitalisations OR outpatient visits, ≥1 in a specialist clinic | 0.981 | 0.979 | 0.999 | 0.983 | 0.976 | 0.999 | 0.964 | 1.000 | 0.999 |
| ≥2 hospitalisations within 1 year | 0.531 | 0.980 | 0.982 | 0.525 | 0.977 | 0.982 | 0.573 | 1.000 | 0.986 |
| ≥2 hospitalisations within 2 years | 0.566 | 0.980 | 0.984 | 0.565 | 0.977 | 0.983 | 0.573 | 1.000 | 0.986 |
| ≥2 outpatient visits within 1 year | 0.941 | 0.978 | 0.998 | 0.947 | 0.975 | 0.998 | 0.891 | 1.000 | 0.996 |
| ≥2 outpatient visits within 2 years | 0.963 | 0.977 | 0.999 | 0.968 | 0.974 | 0.999 | 0.927 | 1.000 | 0.998 |
| ≥2 hospitalisations OR outpatient visits within 1 year | 0.961 | 0.975 | 0.999 | 0.962 | 0.972 | 0.999 | 0.955 | 1.000 | 0.998 |
| ≥2 hospitalisations OR outpatient visits within 2 years | 0.976 | 0.975 | 0.999 | 0.979 | 0.972 | 0.999 | 0.955 | 1.000 | 0.998 |
| ≥2 hospitalisations OR outpatient visits, ≥1 in a specialist clinic within 1 year | 0.961 | 0.978 | 0.999 | 0.962 | 0.975 | 0.999 | 0.955 | 1.000 | 0.998 |
| ≥2 hospitalisations OR outpatient visits, ≥1 in a specialist clinic within 2 years | 0.976 | 0.978 | 0.999 | 0.979 | 0.976 | 0.999 | 0.955 | 1.000 | 0.998 |
| ≥2 hospitalisations within 1 year and medication* | 0.508 | 0.981 | 0.982 | 0.502 | 0.979 | 0.981 | 0.545 | 1.000 | 0.985 |
| ≥2 hospitalisations within 2 years and medication* | 0.538 | 0.980 | 0.983 | 0.537 | 0.978 | 0.982 | 0.545 | 1.000 | 0.985 |
| ≥2 outpatient visits within 1 year and medication* | 0.889 | 0.978 | 0.996 | 0.893 | 0.975 | 0.996 | 0.864 | 1.000 | 0.995 |
| ≥2 outpatient visits within 2 years and medication* | 0.906 | 0.977 | 0.996 | 0.910 | 0.974 | 0.996 | 0.882 | 1.000 | 0.996 |
| ≥2 hospitalisations OR outpatient visits within 1 year and medication* | 0.907 | 0.976 | 0.996 | 0.907 | 0.973 | 0.996 | 0.909 | 1.000 | 0.997 |
| ≥2 hospitalisations OR outpatient visits within 2 years and medication* | 0.918 | 0.976 | 0.997 | 0.919 | 0.973 | 0.997 | 0.909 | 1.000 | 0.997 |
| ≥2 hospitalisations OR outpatient visits, ≥1 in a specialist clinic within 1 year and medication* | 0.907 | 0.978 | 0.996 | 0.907 | 0.975 | 0.996 | 0.909 | 1.000 | 0.997 |
| ≥2 hospitalisations OR outpatient visits, ≥1 in a specialist clinic within 2 years and medication* | 0.918 | 0.978 | 0.997 | 0.919 | 0.975 | 0.997 | 0.909 | 1.000 | 0.997 |
Specificity was 0.999 or 1.000 for all algorithms.
*Medication includes any dispensing for a disease-modifying antirheumatic drug, glucocorticoid, or non-steroidal anti-inflammatory drug listed in the prescription drug register (see online supplementary appendix for detailed list).
NPV, negative predictive value; PPV, positive predictive value; SLE, systemic lupus erythematosus.